What Does PSA Density Mean?

PSA density is a single calculation. Take the total PSA level from your blood test, in nanograms per milliliter (ng/mL). Divide it by the prostate volume, in cubic centimeters (cc). The result is reported as ng/mL/cc.

The reason for the math is simple. PSA, or prostate-specific antigen, is not made only by cancer. Normal prostate tissue makes it too, so a large gland makes more of it than a small one. Benign prostatic hyperplasia, or BPH, is the non-cancerous enlargement that becomes common with age, and it pushes PSA up on its own. Dividing by volume asks a sharper question: is this PSA higher than the size of the gland can explain?

StatPearls states the working rule plainly: a PSA density of 0.15 or more is considered suspicious for cancer.

The related StatPearls review of biomarker testing fills in the range around it. Values of 0.1 to 0.15 ng/mL/cc or higher mark meaningfully raised risk, with 0.15 acting as the usual decision point. Values below 0.09 ng/mL/cc point the other way, with a risk under about 4%.

Read those numbers as a slope, not a wall. A density of 0.20 does not prove cancer, and 0.08 does not rule it out. The number shifts how strongly a biopsy is favored.

Prostate volume is measured on MRI or on transrectal ultrasound. StatPearls gives the formula used: width in cm, times height in cm, times length in cm, times 0.52. That last factor treats the gland as an ellipsoid, which is close to its real shape.

Two practical consequences follow. First, your density changes if the volume is remeasured on a different study. Second, MRI and ultrasound can produce different volumes for the same gland, which moves the density up or down without anything happening to your prostate.

So when you see a density in a report, ask two things: which imaging study supplied the volume, and what date it was done.

PSA density does its most useful work in one specific spot. Multiparametric MRI scores suspicious areas from PI-RADS 1 to PI-RADS 5. PI-RADS 3 is the equivocal middle score, where the images neither reassure nor alarm.

StatPearls describes using PSA density exactly there: to help decide about biopsy in men with a PI-RADS 3 lesion and a moderately raised PSA in the 4 to 10 ng/mL range. That band is often called the grey zone, because a large share of men in it do not have cancer.

The same review lists other tools used in that grey zone: the 4Kscore, the Prostate Health Index, SelectMDx, ExoDx Intelliscore, and ConfirmMDx. Listing is not endorsement — these are commercial tests, and which of them your urologist uses, and whether your insurer pays, varies a great deal. Two of those, SelectMDx and ExoDx, are urine tests.

Because density starts with PSA, anything that alters PSA alters the density.

The largest effect is from 5-alpha-reductase inhibitors, meaning finasteride and dutasteride, taken for BPH or hair loss. StatPearls reports these drugs cut PSA by about 50%, with the full effect taking 6 to 12 months, and it advises doubling the value for screening purposes. That correction is your clinician's to apply, not a sum to do at home, and it is approximate rather than exact. If nobody knows you take finasteride, your density can look falsely reassuring.

Other listed influences include prostatitis, meaning inflammation of the prostate, and recent ejaculation. StatPearls also names statins, NSAIDs, acetaminophen, thiazide diuretics, and obesity as factors that can shift PSA in one direction or the other.

Bring your full medicine list, including anything for hair loss, to the visit where the density is discussed.

Density is one of several ways to reinterpret a PSA number. StatPearls lists the others with real thresholds.

• Age-specific ranges at the 95th percentile: 2.5 ng/mL or less for ages 40 to 49, 3.5 for 50 to 59, 4.5 for 60 to 69, and 6.5 for 70 to 79.
• Percent free PSA, used when total PSA is 4 to 10 ng/mL. Under 10% free carries roughly a 50% cancer risk. Over 25% free carries under 10%.
• PSA velocity, the rate of rise. A yearly increase of no more than 0.75 ng/mL, and no more than 25%, is considered acceptable.
• PSA doubling time. Under 3 months correlates with a much higher risk of dying from prostate cancer.

NCI's screening summary for clinicians describes 4 ng/mL as the standard US threshold that triggers further evaluation. It also documents the cost of casting a wide net. Screening with PSA, digital rectal exam, or both leads to overdiagnosis, meaning cancers found that would never have caused symptoms. The European Randomized Study measured overdiagnosis at roughly 30% in its Finnish center, against a mortality reduction of about 20% in some trials.

PSA density exists to shrink that gap, by pushing biopsies toward men whose PSA is genuinely out of proportion to their gland.

Biopsy results are reported as a Grade Group, which NCI maps to the older Gleason scoring in its treatment summary. Grade Group 1 is a Gleason score of 6 or below. Grade Group 2 is Gleason 3+4=7, and Grade Group 3 is Gleason 4+3=7. Grade Group 4 is Gleason 8, and Grade Group 5 is Gleason 9 or 10.

The order inside a 7 matters, which is why 3+4 and 4+3 sit in different groups.

• What total PSA and what prostate volume were used, and on what dates?
• Was the volume from MRI or ultrasound?
• What was my PI-RADS score, if I had an MRI?
• Am I on finasteride or dutasteride, and was my PSA adjusted for it?
• Given this density, is biopsy being recommended, deferred, or replaced by another test?

For related reading, see Pathology Reports, Imaging Tests, and Biomarker Testing and Precision Medicine.

• StatPearls (NCBI Bookshelf) — Prostate-Specific Antigen
• StatPearls (NCBI Bookshelf) — Biomarker Assays for Elevated Prostate-Specific Antigen Risk Analysis
• National Cancer Institute — Prostate Cancer Screening (PDQ), Health Professional Version
• National Cancer Institute — Prostate Cancer Treatment (PDQ), Health Professional Version